MENLO PARK, Calif., June 25 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing, and commercializing products that address conditions affecting the ear, nose and throat (ENT) today announced the completion of a study evaluating the treatment of patients with Balloon Sinuplasty(TM) technology in the office setting. The prospective, multi-center comparative study evaluated the safety, effectiveness, and cost of performing sinus surgery in the office versus in a hospital operating room setting.
“We are very pleased to have completed this study demonstrating that physicians can successfully treat patients in the office setting using our enabling technology,” said Bill Facteau, President and CEO of Acclarent. “We look forward to partnering with physicians in delivering quality, cost-effective healthcare in the office, which offers the potential for significant savings for our healthcare system.”
About Acclarent
Acclarent is a global medical technology company dedicated to the development of innovative products to further meet the needs of ENT surgeons and their patients.
Acclarent’s initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. With the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel technologies in all areas of ENT. Acclarent markets and sells its products worldwide and our technology has been used by thousands of physicians.
For more information about Acclarent, visit www.Acclarent.com.
CONTACT: Investor Relations, George Harter, Chief Financial Officer of
Acclarent, Inc., +1-650-687-5859
Web site: http://www.acclarent.com/
